Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00268255
Trial of Iressa in Prostate Cancer Patients
- Conditions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00265070
- Locations
- 🇨🇦
Research Site, Montreal, Canada
Phase II Iressa & Carbo/Gem in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00264498
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Iressa v BSC (Best Supportive Care) in First Line NSCLC
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 216
- Registration Number
- NCT00259064
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
- Conditions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 30
- Registration Number
- NCT00258297
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Phase II Iressa Versus Vinorelbine (INVITE)
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT00256711
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00255476
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00255489
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 185
- Registration Number
- NCT00255463
- Locations
- 🇬🇧
Research Site, Poole, United Kingdom
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00252811
- Locations
- 🇮🇹
Research Site, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.